Madrigal Pharmaceuticals
MDGL
#2348
Rank
A$9.74 B
Marketcap
$447.03
Share price
-4.66%
Change (1 day)
80.04%
Change (1 year)

P/E ratio for Madrigal Pharmaceuticals (MDGL)

P/E ratio as of November 2024 (TTM): -14.9

According to Madrigal Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.8756. At the end of 2022 the company had a P/E ratio of -16.8.

P/E ratio history for Madrigal Pharmaceuticals from 2007 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-16.8190.43%
2021-5.80-31.7%
2020-8.49-49.2%
2019-16.7-67.22%
2018-51.041.14%
2017-36.16766.18%
2016-0.526342.81%
2015-0.3685-87.62%
2014-2.98-27.83%
2013-4.13-51.51%
2012-8.5182.21%
2011-4.67-29.03%
2010-6.58-404.32%
20092.16-196.81%
2008-2.2333.68%
2007-1.67

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.9953-93.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.06-59.27%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.